Sr Scientist, Antibody Engineering at Alligator Bioscience
Dr. Mattias Levin has a MSc in Biotechnology and obtained his Ph.D. in Immunotechnology from Lund University. He joined Alligator Bioscience 5 years ago, where his work is primarily focused on the discovery of Alligators new antibody-based drug candidates and bringing them from the benchtop into the clinic.
Alligator Bioscience is dedicated to development of antibody-based therapeutics, with full focus on novel immune oncology solutions. To facilitate this work, Alligator has a strong technology platform, including its newest addition RUBY™, a novel tetravalent plug-and-play bispecific format with very favorable developability properties.
Title: Neo-X’: A bispecific antibody concept targeting CD40 and tumor antigens to enhance neoantigen cross-presentation and T cell priming.
- Alligator has developed a novel concept, Neo-X’, to enable antigen presenting cells to efficiently enhance priming of neoantigen-specific T cells, which may be the missing aspect in tumors that lack T cell infiltration. We hypothesize that binding of the CD40 x TAA bsAb to CD40 on DCs and TAAs on tumor exosomes or tumor debris leads to i) activation of the DC, ii) uptake of the tumor material, iii) cross-presentation of tumor-derived neoantigen (present in exosomes or debris) and iiii) priming of tumor neoantigen-specific T cells, resulting in an increased quantity and/or quality of the tumor-targeting T cell pool.
- The bispecific antibodies targeting CD40 and tumor antigens have been built using Alligators RUBY™ format. RUBY is a novel plug-and-play tetravalent bispecific format with favorable developability and manufacturability properties.
- We have generated an extensive data package containing in vivo and in vitro data supporting the concept. This demonstrates the potential of Neo-X´ to, by targeting CD40 and a tumor specific antigen, mediate an expansion of the tumor-specific T cell repertoire and thereby induce T cell infiltration and potent anti-tumor effects.